Skip to content

EDESA BIOTECH, INC.: 10-Q filed 2019-08-14

What EDESA BIOTECH, INC. reported in its quarterly report filed 2019-08-14 (fiscal Q2 2019): 31 published measures, 88 facts as tagged in accession 0001654954-19-009578.

This filing

Form
10-Q (quarterly report)
Filed
2019-08-14
Fiscal period
fiscal Q2 2019
Accession
0001654954-19-009578 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All EDESA BIOTECH, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-06-307,227,620USD
At 2018-12-313,398,310USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-06-306,212,616USD
At 2018-12-313,214,490USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-06-306,363,096USD
At 2018-12-313,367,098USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-1,294,007USD91
2019-01-01 to 2019-06-30-1,822,837USD181
2018-04-01 to 2018-06-30-411,840USD91
2018-01-01 to 2018-06-30-827,096USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-01-01 to 2019-06-30-3,519,361USD181
2018-01-01 to 2018-06-30-687,974USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2019-01-01 to 2019-06-302,267USD181
2018-01-01 to 2018-06-306,869USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2019-04-01 to 2019-06-30500USD91
2019-01-01 to 2019-06-30500USD181
2018-04-01 to 2018-06-300USD91
2018-01-01 to 2018-06-300USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2019-01-01 to 2019-06-306,405,207USD181
2018-01-01 to 2018-06-30-6,869USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-06-30-5,780,718USD
At 2018-12-31-3,761,595USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2019-06-3088,589USD
At 2018-12-317,386USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-04-01 to 2019-06-3011,000USD91
2019-01-01 to 2019-06-3024,866USD181
2018-04-01 to 2018-06-3023,000USD91
2018-01-01 to 2018-06-3046,680USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-1,320,354USD91
2019-01-01 to 2019-06-30-1,861,128USD181
2018-04-01 to 2018-06-30-421,993USD91
2018-01-01 to 2018-06-30-853,288USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-06-307,123,691USD
At 2018-12-313,390,924USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-06-301,015,004USD
At 2018-12-31183,820USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-04-01 to 2019-06-301,320,854USD91
2019-01-01 to 2019-06-301,861,628USD181
2018-04-01 to 2018-06-30421,993USD91
2018-01-01 to 2018-06-30853,288USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2019-06-3077,913USD
At 2018-12-310USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-04-01 to 2019-06-30502,927USD91
2019-01-01 to 2019-06-30614,629USD181
2018-04-01 to 2018-06-30298,223USD91
2018-01-01 to 2018-06-30578,268USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-06-307,504,468shares
At 2018-12-313,239,902shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2019-06-306,363,096USD
At 2018-12-313,367,098USD
At 2018-06-303,937,759USD
At 2017-12-315,000,122USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-06-30317,560USD
At 2018-12-31230,792USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2019-06-30-329,277USD
At 2018-12-31-429,973USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2019-06-306,212,616USD
At 2019-03-312,772,359USD
At 2018-12-313,214,490USD
At 2018-06-303,855,377USD
At 2018-03-314,224,230USD
At 2017-12-314,998,540USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2019-06-3046,500USD
At 2018-12-3110,406USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2019-06-3027,911USD
At 2018-12-313,020USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2019-06-3015,340USD
At 2018-12-310USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2019-01-01 to 2019-06-30-1,822,837USD181
2018-01-01 to 2018-06-30-827,096USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-1,266,564USD91
2019-01-01 to 2019-06-30-1,722,141USD181
2018-04-01 to 2018-06-30-392,322USD91
2018-01-01 to 2018-06-30-1,189,843USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-04-01 to 2019-06-30817,927USD91
2019-01-01 to 2019-06-301,246,999USD181
2018-04-01 to 2018-06-30123,770USD91
2018-01-01 to 2018-06-30275,020USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2019-04-01 to 2019-06-301,600USD91
2019-01-01 to 2019-06-302,500USD181
2018-04-01 to 2018-06-30400USD91
2018-01-01 to 2018-06-301,000USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2019-04-01 to 2019-06-3026,347USD91
2019-01-01 to 2019-06-3038,291USD181
2018-04-01 to 2018-06-3010,153USD91
2018-01-01 to 2018-06-3026,192USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-06-30116,991USD181
2018-01-01 to 2018-06-30-3,977USD181

Inspect the source

Entity
EDESA BIOTECH, INC. / CIK 0001540159
Captured
2026-09-20T09:17:32.413Z
SEC response SHA-256
0f44de1ccf1eff46a1af17dc21d4a3bb38216bbf46e813f5a136d29e08bfd65d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001540159.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))